Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2018
Price : $35 *
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 25 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2014 New trial record